Citation:P N. Kesav,Cara E. Capitena Young,Monica K. Ertel,Leonard K. Seibold,Malik Y. Kahook.Sustained-release drug delivery systems for the treatment of glaucoma.Int J Ophthalmol 2021;14(1):148-159,doi:10.18240/ijo.2021.01.21
Sustained-release drug delivery systems for the treatment of glaucoma
Received:June 12, 2020  Revised:September 17, 2020
Email this Article  Add to Favorites  Print
DOI:10.18240/ijo.2021.01.21
Key Words:glaucoma  drug delivery  sustained release
Fund Project:
              
AuthorInstitution
Natasha P. Kesav Department of Ophthalmology, University Hospitals Cleveland Medical Center, Cleveland, OH 44106, USA
Cara E. Capitena Young Department of Ophthalmology, University of Colorado School of Medicine, CO 80045, USA
Monica K. Ertel Department of Ophthalmology, University of Colorado School of Medicine, CO 80045, USA
Leonard K. Seibold Department of Ophthalmology, University of Colorado School of Medicine, CO 80045, USA
Malik Y. Kahook Department of Ophthalmology, University of Colorado School of Medicine, CO 80045, USA
Hits: 582
Download times: 59
Abstract:
      Glaucoma, a leading cause of irreversible blindness, affects more than 64 million people worldwide and is expected to grow in number due to the aging global population and enhanced methods of detection. Although topical therapies are often effective when used as prescribed, the drawbacks of current medical management methods include poor patient adherence, local and systemic side effects, and in some cases, limited therapeutic efficacy. Novel ocular drug delivery platforms promise to deliver differentiated drug formulations with targeted delivery leveraging patient-independent administration. Several platforms are in various stages of development with promising pre-clinical and clinical data. The Bimatoprost Sustained Release (SR) intracameral implant was approved in the United States in March of 2020, making it the first long-term injectable therapy available for the treatment of glaucoma. This review aims to provide an update on novel sustained release drug delivery systems that are available today as well as those that might be commercialized in coming years.
PMC FullText Html:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7790669/
Supplementary Material
PDF Fulltext  Download reader  HTML Fulltext   View/Add Comment